The expression of c-myc is deregulated in Burkitt's lymphoma by the translocation t(8;14). Most of the increased c-myc expression is from the P1 promoter, which is normally a minor promoter. How the P1 promoter is activated by the immunoglobulin heavy chain gene enhancers is not understood. We identified a YY1 site in the immunoglobulin heavy-chain gene HS3 enhancer, which increased c-myc P1 promoter activity, and a MARE site, which decreased c-myc P1 activity. Small Maf proteins bound to the MARE site both in vitro and in vivo, recruited histone deacetylase 2, and resulted in deacetylation of histones H3 and H4 at the c-myc promoter region. In contrast, YY1 recruited CBP and increased histone acetylation at the c-myc promoter. Rb interacts with YY1 to prevent DNA binding in normal B cells, but no significant interaction with YY1 was detected in Burkitt's cells, and binding of YY1 to the HS3 enhancer was observed by chromatin immunoprecipitaton. Increased expression of MafK and/or decreased expression of YY1 by silencing RNA downregulated endogenous c-myc mRNA levels and increased the sensitivity of the cells to doxorubicin. Mutation of the major active sites (nuclear factorkappa B and YY1) in the enhancers prevented c-myc activation.
Introduction
A translocation of the c-myc gene into one of the immunoglobulin gene loci characterizes Burkitt's lymphoma. The most common form of the translocation is the t (8;14) , which links the c-myc gene to the immunoglobulin heavy-chain gene (IgH). The translocated c-myc gene is deregulated and highly expressed with transcription from the P1 promoter increasing to a greater extent than that from the normal P2 promoter. It is thought that the physical linkage of the c-myc gene to the IgH locus promotes the interaction between regulatory elements in the c-myc promoter region and the IgH enhancers. The four IgH 3 0 enhancers (HS1-4) cause deregulated c-myc expression and the promoter shift from P2 to P1 when they are linked to the c-myc promoter in an episomal vector. 1, 2 Most of the cis-acting promoter and enhancer elements that contribute to the deregulated expression of c-myc remain to be identified. We have shown that an nuclear-factor kappa B (NF-kB) site in the HS4 region of the IgH enhancer is involved in the activation of the c-myc gene and that it activates the promoter shift from P2 to P1. 2 The HS3 region also activates the promoter shift from P2 to P1, but the regulatory elements responsible for this are not known. Further investigation of the regulatory elements in the HS3 enhancer region was performed to identify those responsible for the c-myc promoter shift. Two sites were identified, one that activated c-myc P1 promoter activity and one that repressed the P1 promoter. The positive regulatory site was a site for the Yin Yang 1 (YY1) transcription factor. YY1 interacts with many cofactors including histone acetyl transferases (HATs) and histone deacetylases (HDACs) and can function as a transcriptional repressor or activator.
3 YY1 forms a complex with the retinoblastoma protein (Rb), and this inhibits the interaction of YY1 with DNA. 4 Overexpression of YY1 in growth-arrested coronary artery smooth muscle cells stimulates the cells to enter S phase of the cell cycle, and very little of the complex of YY1 with Rb is detected in S phase. 4 In Burkitt's cells, we found that YY1 was not bound to Rb and was present at the HS3 enhancer site in vivo.
The negative regulatory site was identified as a Maf recognition element, which consists of two different types of sites, C-MARE and T-MARE. The Maf family of transcription factors is divided into the large and small Maf subfamilies. These are basic leucine zipper proteins, and the large Maf proteins possess an N-terminal transactivation domain whereas the small Maf proteins, MafF, MafG, and MafK, lack transactivation domains. Small Maf proteins can form homodimers or heterodimers among themselves, and they can also heterodimerize with other basic leucine zipper proteins, including Fos family members, Bach and other CNC proteins.
Materials and methods

Cell lines and samples
Raji is a human Burkitt's cell line with the translocation t (8;14) . The Burkitt's samples were obtained from patients after informed consent using a protocol approved by the Human Subjects Institutional Review Board. The samples were purified and stored as frozen viable cells.
Plasmid constructs
The construct of the c-myc promoter linked to the IgH enhancer regions HS1-4 has been described previously. 2 The episomal plasmids contain the Epstein-Barr virus replication origin and hygromycin B resistance gene. The 5 0 deletions of HS3 were created by polymerase chain reaction (PCR) amplification using primers based on different regions of the enhancer. The MafK expression vector contains the cytomegalovirus promoter.
Site-directed mutagenesis
The C-MARE and YY1 sites in MHS3 were mutated by the oligonucleotide-directed mutagenesis method with the Quick Change Kit from Stratagene.
The primer used for the C-MARE site was: CAACCCAGAC CATGCTGAGAAGGGCACGCATCACCC. (The mutated bases are underlined.) The primer used for the YY1 site was: CACTCGTGCCTTAGTGAGGTGGCGTTCTGTCCCAATG.
Transfections
The luciferase assay protocol was as reported previously. 5, 6 Transfections were performed as described previously with selection of stably transfected cells in 0.5 mg/ml of hygromycin for 1 week. Stably transfected pools were maintained in 0.1 mg/ml of hygromycin B. Episomal copy number was determined by Southern blot analysis of XhoI and MunI-digested DNA hybridized with a 1.2 kb XhoI-HindIII human c-myc probe. The transfection results are represented as the average and standard deviation. Cotransfection studies were performed with a green fluorescent protein expression vector, and transfected cells were selected with a FACSVantage SE cell sorter. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Electrophoretic mobility shift assay
The double-stranded oligonucleotides used for competition and the electrophoretic mobility shift assay (EMSA) conditions have been previously described. 2 The oligonucleotides of the HS3 MARE and YY1 sites, consensus sites, and the mutated sites are listed in Supplementary Table 1 . For DNA competition experiments, a 100-fold molar excess of unlabeled oligonucleotide was added, and for the supershift experiments, 1 mg of antibody was added to the binding reaction with incubation for 1 h at 41C. All antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) (listed in Supplementary Table 2 ).
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was performed as outlined previously. 6, 7 Antibodies for acetyl histone H3 and H4 were from Upstate Biotechnologies. Realtime PCR was performed to quantify the amount of immunoprecipitated DNA. The primers and probes are listed in Supplementary Table 3 . All quantitative ChIP assay results are presented as the average and standard deviation from at least three independent immunoprecipitations with duplicate realtime PCR analysis.
Immunoprecipitation and Western blot analysis
For Western analysis, lysates were precleared by incubation with protein G-Sepharose (Zymed, South San Francisco, CA, USA) for 1 h at 41C. The precleared lysates were then incubated with 2 mg of antibody against the small Maf proteins or an antibody against YY1. Twenty-five microliters of protein G-Sepharose was added to the lysates and after incubation for 1 h at 41C, the protein G-Sepharose was centrifuged and washed twice before preparation for electrophoresis. This was followed by Western blotting with antibodies against small Maf proteins, HDAC2 and mSin3A or with antibodies against Rb and YY1.
Promoter usage analysis
Transcripts from the c-myc P1 promoter and total transcripts from both P1 and P2 promoters were measured by real-time reverse transcriptase (RT)-PCR as described previously. 8 All quantitative real-time PCR results are presented as the average and s.d. from at least three independent experiments with duplicate PCR analysis.
Silencing RNA analysis and RT-PCR
The sequence of the antisense strands of siRNA were:
anti-MafG/K: CTCCTTCTGCGTCACCCGC nonspecific: GTGTCCGGACCGCCTTGCA The silencing RNA (siRNA)s were synthesized using the Silencer siRNA construction kit from Ambion (Austin, TX, USA). The predesigned siRNA for YY1 was obtained from Ambion. Transfection of the siRNAs and 1 mg of a GFP expression vector was by electroporation using solution T with the Amaxa Biosystems (Gaithersburg, MD, USA) electroporator. After incubation for 16-20 h in culture medium, the cells were sorted by GFP expression on a FACSVantage SE. For the luciferase assay, 500-2000 ng of protein was used. In addition, RNA and protein were extracted. The levels of small MafG/K, YY1, and c-myc were determined by real-time PCR with normalization to GAPDH. The primers and probe for Maf are shown in Supplementary Table 3 . The c-myc and YY1 primer sets were from Applied Biosystems (Foster City, CA, USA).
Results
Identification of two sites in the IgH enhancer HS3 that regulate c-myc promoter activity
We have previously shown that the IgH 3 0 enhancers increased c-myc promoter activity and that the enhancer regions HS3 and HS4 contributed to the promoter shift from P2 to P1. A binding site for NF-kB in HS4 played a major role in the activity and promoter shift of this enhancer region. 2 To investigate the active sites in HS3, several deletion constructs of HS3 were linked to the c-myc promoter ( Figure 1a ) and assayed for activity. We identified a 25-bp region between constructs 3 and 4 that exhibited a negative regulatory effect in both transient and stable transfections and a 25-bp region between constructs 6 and 7 that had a positive effect (Figure 1b ).
In vitro protein binding and functional activity of the two sites in HS3
A potential C-MARE site was located in the region between constructs 3 and 4 ( Figure 1a ) that downregulated c-myc promoter activity. To identify proteins that bound to this region in vitro, EMSA was performed. As shown in Figure 2a , three major complexes were identified. Competition with the wildtype sequence and a consensus MARE site resulted in loss of the three complexes on EMSA ( Figure 2a , lanes 2 and 5, respectively), whereas a mutated MARE site in the HS3 sequence or the consensus sequence or a nonspecific sequence had no effect ( A similar result was obtained with an antibody against c-AMP response element-binding protein (CREB) (data not shown). These results suggest that small Maf proteins bind to this region of HS3 as homodimers (the faster migrating bands) and as heterodimers with AP-1 family proteins (the more slowly migrating complex).
EMSA was performed with double-stranded oligonucleotides of the region of the HS3 enhancer between constructs 6 and 7 ( Figure 1a) . A potential binding site for the YY1 transcription factor was identified in this region. As shown in Figure 2c , a single complex was observed in EMSA. Competition with a nonspecific sequence or a sequence with a mutation in the YY1 site had no effect (Figure 2c, lanes 2 and 3, respectively) . A 100-fold molar excess of the wild-type sequence or a consensus YY1 sequence resulted in loss of the complex (Figure 2c , lanes 4 and 5, respectively), and addition of an antibody to YY1 resulted in a diminishment of the complex and a supershifted band was observed (Figure 2c , lane 6). These findings suggest that YY1 binds to the region of HS3 that has a positive regulatory effect on the c-myc promoter.
To confirm the importance of the YY1 site in the IgH enhancer HS3, luciferase assays were performed. Mutation in the YY1 sequence resulted in a lack of protein binding ( Figure 2c , lane 3), and incorporation of this mutation into the c-myc promoterIgH enhancer construct decreased the activity of the c-myc promoter by approximately 50% (Supplementary Figure 1a) . We have previously shown that a site for NF-kB in the enhancer HS4 was important for c-myc promoter activity, and mutation of this site decreased c-myc promoter activity by approximately 70% (Supplementary Figure 1a) . Mutation of the YY1 and NF-kB sites together caused a 90% reduction in c-myc promoter activity (Supplementary Figure 1a) . Mutation of the core MARE site prevented protein binding (Figure 2a, lane 3) , and when this mutation was incorporated into the c-myc promoter-IgH enhancer construct, c-myc promoter activity increased by threefold. Mutation of the C-MARE and YY1 sites together decreased c-myc promoter activity to approximately 75% of that of the wild-type construct, suggesting that the effect of the YY1 site is greater than the effect of the C-MARE site (Supplementary Figure 1a) .
Another MARE site (T-MARE) was identified in HS3, and there is a C-MARE site in HS4, which has been described as a negative regulator of the IgH promoter. 9 Mutation of the HS3 C-MARE site consistently increased c-myc promoter activity whether irrespective the other MARE sites were mutated (Supplementary Figure 1b) .
In vivo interaction of Maf , YY1 co-repressors and co-activators with the HS3 region
ChIP studies were performed to identify the proteins that bound to the HS3 enhancer region in vivo in the stably transfected Raji cell lines containing episomal constructs of the c-myc promoter with the IgH 3 0 enhancers. Because the C-MARE and YY1 sites are separated by less than 100 bp, they are likely to be precipitated on the same DNA fragment. A single set of primers was used to perform ChIP assays of this region. Binding of Maf to the wild-type site was clearly detected, but there was essentially no binding above background to the mutated site (Figure 3a) . Low levels of c-Jun and ATF-2 were detected at the wild-type site, but no significant binding was observed at the mutated site (Figure 3a) . Binding of YY1 to this region of HS3 was also detected (Figure 3a) . When the YY1 site was mutated, binding of YY1 was not observed above the background level. These results suggest that small Maf family members bind to the wild-type C-MARE site in vivo and that there is a small amount of binding by c-Jun and ATF-2 to this site. In addition, YY1 binds in vivo to the YY1 site in the HS3 enhancer region, and the binding is diminished when the site is mutated. As a control, the same antibodies were used in enhancer region HS12 near a binding site for NF-kB, and no binding above background was observed for Maf, c-Jun, ATF or YY1 (Supplementary Figure 2) .
To determine whether the HS3 C-MARE and YY1 sites influenced the acetylation status of histones at the c-myc promoter, quantitative ChIP assays were performed with antibodies against acetylated histone H3 and H4 and two different primer sets that recognized the episomal c-myc promoter. Interestingly, mutation of the C-MARE site increased the amount of acetylated histone H3 at the c-myc promoter by 3-to 4-fold and of acetylated histone H4 by 2-to 3-fold (Supplementary Figure 3a and b) . These results are consistent with the increase in c-myc promoter activity that is observed with mutation of the C-MARE site. Mutation of the YY1 site decreased the binding of acetylated histones H3 and H4 at the c-myc promoter by 2-to 3-fold (Supplementary Figure  3a and b) .
Based on the changes in histone acetylation at the c-myc promoter that were observed, we performed ChIP assays to examine whether any histone deacetylases or histone acetyl transferases bound to the HS3 MARE site. HDAC2 was associated with the MARE site on the wild-type construct but decreased binding was observed with the mutated MARE site construct (Figure 3b ). In addition, we observed binding of mSin3A at higher levels to the wild-type MARE site compared to the mutated site (Figure 3b) . CBP is known to interact with YY1, so we examined its binding to the wild-type HS3 region. Significant levels of CBP were bound, and the binding was decreased with mutation of the YY1 site ( Figure 3b ). As shown in Supplementary Figure 2 , HDAC2 and mSin3A did not bind to the HS12 region, whereas CBP did, but mutation of the MARE or YY1 sites in HS3 had no effect on the binding. To determine whether the small Maf proteins interacted directly with HDAC2, co-immunoprecipitation studies were performed. The results revealed that both HDAC2 and mSin3A precipitated with small Maf proteins (Figure 4a ).
No detectable interaction of YY1 with Rb in Burkitt's cells
Rb, particularly the hypophosphorylated form, binds to YY1 in smooth muscle cells 4 and in B cells and interferes with its binding to DNA. 10 We observed binding of YY1 to the HS3 region in vivo in Raji cells (Figure 3a) , so we examined whether Rb bound to YY1. Extracts from resting B cells, Raji cells, or two primary Burkitt's lymphoma samples were incubated with an antibody to YY1. Western blotting of the immunoprecipitate revealed that Rb bound to YY1 in the resting B cells, but no Rb was observed in the YY1 immunoprecipitate in Raji or primary Burkitt's cells (Figure 4b ). Rb was expressed in the Raji and Burkitt's cells although the levels were somewhat reduced compared to the resting B cells, and the migration was slower consistent with the presence of the hyperphosphorylated form of Rb (Figure 4b, lower panel) . 
Maf and YY1 proteins influence promoter usage at the c-myc promoter
The four IgH 3 0 enhancers cause a shift in c-myc promoter usage from P2 to P1. In normal cells, the ratio of P1 to P2 is approximately 0:12, whereas in the presence of the enhancers it increases to approximately 1.2:1.4. Real-time RT-PCR was performed to examine whether the MARE and YY1 sites caused a change in c-myc promoter usage. Quantitation and normalization for the number of episomal vector copies revealed that the P1 to P2 ratio increased from 1.4 to 3.8 with mutation of the MARE site (Supplementary Figure 4) . Although the activity of the P2 promoter increased slightly (1.25-fold), most of the increase in the ratio was from increased activity of the P1 promoter. Mutation of the YY1 site decreased the activity of the P1 promoter with very little effect on the P2 promoter such that the P1 to P2 ratio decreased to approximately 0.7 (Supplementary Figure 4) . Mutation of the YY1 and NF-kB sites together resulted in a decrease in transcripts from both promoters, and the P1 to P2 ratio decreased to 0.24.
To examine the effect of reduced levels of small Maf proteins and YY1 on the c-myc promoter, siRNA studies were performed. The Maf siRNA was designed to interfere with the expression of MafG and MafK. (Raji cells express MafG and MafK, but not MafF). The level of expression of small Maf proteins was decreased to 20% of baseline whereas a control siRNA had no effect (Figure 5a ). In the presence of the small Maf siRNA, the activity of the c-myc promoter IgH enhancer construct was increased by approximately 2.5-fold if the MARE site was intact (Figure 5c ). Mutation of the MARE site increased the promoter activity as expected, but there was no significant change in c-myc promoter activity in the presence of the small Maf siRNA (Figure 5c ). These results demonstrate that MafG/K are required for the repressive activity of the MARE site in the IgH HS3 region. The YY1 siRNA decreased YY1 expression by approximately 85% (Figure 5b) , and when the YY1 site was intact, the activity of the c-myc promoter was decreased by approximately 50% (Figure 5c ). The YY1 siRNA had no effect on the c-myc promoter activity when the YY1 site in HS3 was mutated (Figure 5c ). 
Activation of c-myc H-M Hu et al
Increased levels of MafK and decreased levels of YY1 decrease endogenous c-myc expression and enhance apoptosis
We used an expression vector for MafK to determine whether increased levels resulted in decreased c-myc promoter activity. As shown in Figure 6a , a decrease in c-myc promoter activity was observed with increasing levels of the MafK expression vector. This effect was not observed with the construct with the mutated HS3 MARE site (data not shown). The level of endogenous c-myc mRNA was also decreased by overexpression of MafK (Figure 6b ). In addition, decreased expression of YY1 by siRNA against it resulted in decreased endogenous c-myc levels in Raji cells but not in cells that lack a c-myc translocation (Figures 6b and c) . A further decrease in c-myc expression was observed with the combination of a MafK expression vector and siRNA to YY1 (Figure 6b ). Decreased levels of c-myc correlate with impaired growth and survival of Burkitt's lymphoma cells, for example. 11, 12 We investigated whether the cells with overexpression of MafK or decreased expression of YY1 showed any change in survival with doxorubicin treatment. As shown in Figure 6d , significantly more cell death was observed with increased MafK expression and with decreased levels of YY1. It is likely that the expression of genes in addition to c-myc changes with MafK overexpression; however, at least some of the increased susceptibility to doxorubicin was due to the level of c-Myc. Transfection of a c-Myc expression vector improved the survival of Burkitt's cells in the presence of doxorubicin (Figure 6d ).
Discussion
The IgH enhancers deregulate expression of the c-myc gene in Burkitt's lymphoma. Several of the positive regulatory sites that are involved in this deregulation have been located. 2, 13 We have now identified two additional regulatory sites in the IgH HS3 enhancer that regulate the activity of the c-myc P1 promoter. The mechanisms involved in the exclusive activation of the P1 promoter but not of the P2 promoter are unclear. Small Maf proteins bound to the negative regulatory site both in vitro and in vivo and caused a degree of histone deacetylation at the c-myc promoter. We found that HDAC2 and mSin3A bound with small Maf proteins to the MARE site. Presumably these contribute to the deacetylation of histones at the c-myc promoter.
Linkage of the c-myc gene to the IgH region results in increased histone acetylation of the c-myc promoter and increased transcriptional activity suggesting that the positive regulatory sites in the IgH enhancers have a greater impact than the negative regulatory ones. We have previously shown that a site for NF-kB in the HS4 enhancer region activates c-myc promoter activity and induces the promoter shift from P2 to P1. 2 In this study, we identified another positive regulatory site that contributes to the activation of the c-myc P1 promoter. YY1 binds to the positive regulatory site in the HS3 enhancer region, recruits CBP to this region, and increases histone acetylation at the c-myc promoter. In normal resting B cells, hypophosphorylated Rb binds to YY1 and prevents it from binding to DNA. We found that there was very little interaction of YY1 with Rb in the Burkitt's cells, most likely because Rb was hyperphosphorylated. YY1 binds to the site in the HS3 region, and the net effect is activation of the c-myc promoter, overriding the negative regulatory Maf-binding site. In normal resting B cells the importance of the negative regulatory Maf site may be greater because Rb binds YY1 and prevents its interaction with the HS3 enhancer site.
Increased levels of MafK or decreased expression of YY1 led to repression of the c-myc promoter linked to the IgH enhancers, and endogenous c-myc mRNA levels were decreased. Enhancing the effectiveness of negative regulatory elements in the IgH enhancers provides a novel approach to downregulate c-myc expression. The negative regulatory elements in enhancers most likely function to silence the enhancer at certain times during B-cell development and/or provide tissue-specific expression. For example, the immunoglobulin k locus has several negative regulatory elements, including a PU.1-binding site. This site is a negative regulator at the pre-B cell stage and a positive regulator at the mature B cell stage of differentiation.
14 One of the negative regulatory sites contributed to tissue specific expression of the k immunoglobulin locus, and mutation of this region increased expression in non-B cells. 14 To begin to examine the consequences of decreased c-Myc expression by overexpression of MafK or inhibition of expression of YY1, we demonstrated that Burkitt's cells were more sensitive to treatment with doxorubicin. Doxorubicin induces topoisomerase-mediated single-and double-strand breaks in DNA. It is known to produce reactive-free radicals and induce oxidative stress. Small Maf proteins bind to the antioxidant response element (ARE), which mediates the transcription of detoxifying enzymes in response to oxidative stress. The ARE is very closely related to the MARE site. Studies have shown that increased expression of small Maf proteins represses genes that are controlled by the ARE. In addition, Bach2, which can form heterodimers with small Maf proteins, promotes oxidative stress-induced cell death, and overexpression of Bach2 increases the sensitivity of cells to chemotherapeutic agents that induce intracellular oxidative stress. 15, 16 Thus, overexpression of small Maf proteins or one of their binding partners, Bach2, influences the response of cells to certain chemotherapeutic agents. We have shown that c-Myc expression is also decreased by overexpression of MafK, and decreased c-Myc levels have been found to contribute to reduced survival of Burkitt's cells. Other studies have shown that the level of expression of small Maf proteins determines whether MARE sites function as positive or negative transcriptional regulators. 17 Modulation of the activity of small Maf proteins is thus a new method to regulate the activity of the IgH enhancers and downregulate c-myc expression.
In summary, we have identified the major sites in the IgH enhancer HS3 that deregulate c-myc expression from the P1 promoter. Our previous studies have shown that the IgH enhancer regions HS3 and HS4 were responsible for the activation of the c-myc P1 promoter. The most active site in the HS4 enhancer region is an NF-kB-binding site. The YY1 site is the most active positive regulatory site in the HS3 enhancer, and we have shown that interference with the binding of transcription factors to the NF-kB and YY1 sites results in the loss of c-myc promoter activation.
